United Therapeutics Corporation Stock News

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2022 financial results before t

United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near t

David Bennett, 57, lived for two months after receiving the experimental organ transplant.

The first person to receive a heart transplant from a pig has died on Tuesday after two months from the landmark surgery at the University of Maryland Medical Center, the hospital…

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will p

Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease | Comunicados | Edición USA | Agencia EFE

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q4 2021 Results - Earnings Call Transcript

United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.

The heavy selling pressure might have exhausted for United Therapeutics (UTHR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street

United Therapeutics Corp (NASDAQ: UTHR ) and its partner MannKind Corp (NASDAQ: MNKD ) have received an FDA information request letter for additional information regarding the pulmonary safety of Tyvaso DPI . United Therapeutics responded to the agency''s information request. However, the FDA has considered this response to be a significant amendment to the NDA, extending FDA''s review deadline to May 2022 … Full story available on Benzinga.com

MannKind (MNKD) said the U.S. Food and Drug Administration ((FDA)) has extended its deadline to May from February to review United Therapeutics'' (UTHR) new drug application ((NDA))…

United Therapeutics (UTHR) delivered earnings and revenue surprises of -37.67% and 1.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (NASDAQ:UTHR) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is $4.05 (+22.4% Y/Y) and

Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.